Kuros Biosciences AG Stock Swiss Exchange
Equities
CH0011025217
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CHF | - |
|
04-24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
04-17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 20.07M 27.37M | Sales 2023 | 33.56M 37.45M 51.07M | Capitalization | 128M 143M 195M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.62M -21.3M | Net income 2023 | -13M -14.51M -19.78M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.64M 33.6M | Net cash position 2023 | 12M 13.39M 18.25M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.91% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Chairman | 67 | 17-05-22 |
1st Jan change | Capi. | |
---|---|---|
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.56B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |